Ironwood Pharmaceuticals provided an update on its first quarter 2015 activities, including their gastrointestinal product candidates.
Here are three highlights from the first quarter:
1. Data from Ironwood's investigational gastric retentive bile acid sequestrant demonstrated improvements in relief of heartburn and other symptoms.
2. Ironwood reported continued activity with a Phase IIa clinical study evaluating the ability of guanylate cyclase-C agonist to provide diabetic gastroparesis symptom relief.
3. Dosing began in a Phase I clinical study of he first clinical compound in a broad library of sGC stimulators for the potential treatment of cardiovascular disease.